Isolation and pharmacological characterization of AdTx1, a natural peptide displaying specific insurmountable antagonism of the α 1A- adrenoceptor

British Journal of Pharmacology

Volumn 159, Issue 2, 2010, Pages 316-325

  Quinton, L ^a,b   Girard, E ^c   Maiga, A ^d   Rekik, M ^e   Lluel, P ^e   Masuyer, G ^f   Larregola, M ^g   Marquer, C ^d   Ciolek, J ^h   Magnin, T ⁱ   Wagner, R ⁱ   Molgo J ^c   Thai, R ^d   Fruchart Gaillard, C ^d   Mourier, G ^d   Chamot Rooke, J ^a   Menez A ^j   Palea, S ^e   Servent, D ^d   Gilles, Nicolas ^d  

^a LABORATOIRE HÉTÉROÉLÉMENTS ET COORDINATION   (France)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c LABORATOIRE DE NEUROBIOLOGIE CELLULAIRE ET MOLÉCULAIRE   (France)

^d SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^e UNIVERSITÉ PAUL SABATIER   (France)

^f University of Bath   (United Kingdom)

^g Centre National de la Recherche Scientifique   (France)

^h NICOLAUS COPERNICUS UNIVERSITY   (Poland)

ⁱ UNIVERSITÉ DE STRASBOURG   (France)

^j MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

more..

Author keywords

1A adrenoceptors; Benign prostatic hyperplasia; Binding experiments; Iodination; Mass fragmentation; Snake toxin; Venom fractionation

Indexed keywords

4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; ALPHA 1A ADRENERGIC RECEPTOR; PEPTIDE DERIVATIVE; PHENYLEPHRINE; PRAZOSIN; PROTEIN ADTX1; RAUWOLSCINE; SNAKE VENOM; UNCLASSIFIED DRUG;

ALPHA ADRENERGIC RECEPTOR BLOCKING; AMINO ACID SEQUENCE; ANIMAL TISSUE; ARTICLE; BRAIN SYNAPTOSOME; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG ISOLATION; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG SYNTHESIS; IODINATION; MALE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; RABBIT; RAT; RECEPTOR AFFINITY; SMOOTH MUSCLE CONTRACTILITY;

AMINO ACID SEQUENCE; ANIMALS; CHEMICAL FRACTIONATION; ELAPID VENOMS; ELAPIDAE; HUMANS; MALE; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PEPTIDES; PICHIA; PROSTATE; RABBITS; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 75649102086     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00532.x     Document Type: Article

References (51)

1. Alexander SP, Mathie A, Peters JA (2008). Guide to receptors and channels, 3rd edition. Br J Pharmacol 153 (Suppl. 2 S1.
2. Andre N, Cherouati N, Prual C, Steffan T, Zeder-Lutz G, Magnin T et al. (2006). Enhancing functional production of G protein-coupled receptors in Pichia pastoris to levels required for structural studies via a single expression screen. Protein Sci 15 : 1115 1126.
3. Banerjee Y, Mizuguchi J, Iwanaga S, Kini RM (2005). Hemextin AB complex, a unique anticoagulant protein complex from Hemachatus haemachatus (African Ringhals cobra) venom that inhibits clot initiation and factor VIIa activity. J Biol Chem 280 : 42601 42611.
4. Birdsall NJ, Lazareno S (2005). Allosterism at muscarinic receptors: ligands and mechanisms. Mini Rev Med Chem 5 : 523 543.
5. Bradley KN (2000). Muscarinic toxins from the green mamba. Pharmacol Ther 85 : 87 109.
6. Bremner JB, Griffith R, Coban B (2001). Ligand design for alpha(1) adrenoceptors. Curr Med Chem 8 : 607 620.
7. Bullock TL, Andriole, GL Jr. (2006). Emerging drug therapies for benign prostatic hyperplasia. Expert Opin Emerg Drugs 11 : 111 123.
8. Chen Z, Rogge G, Hague C, Alewood D, Colless B, Lewis RJ et al. (2004). Subtype-selective noncompetitive or competitive inhibition of human alpha1-adrenergic receptors by rho-TIA. J Biol Chem 279 : 35326 35333.
9. Cheng Y, Prusoff WH (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22 : 3099 3108.
10. Christopoulos A, El-Fakahany EE (1999). Qualitative and quantitative assessment of relative agonist efficacy. Biochem Pharmacol 58 : 735 748.
11. Cooper HJ, Hakansson K, Marshall AG (2005). The role of electron capture dissociation in biomolecular analysis. Mass Spectrom Rev 24 : 201 222.
12. Craig AG, Norberg T, Griffin D, Hoeger C, Akhtar M, Schmidt K et al. (1999). Contulakin-G, an O-glycosylated invertebrate neurotensin. J Biol Chem 274 : 13752 13759.
13. Delaflotte S, Auguet M, Chabrier PE (1996). Pharmacological evidence that different alpha 1 adrenoceptor subtypes mediate contraction in rabbit prostate and hypogastric artery. Acta Physiol Scand 158 : 241 251.
14. le Du MH, Marchot P, Bougis PE, Fontecilla-Camps JC (1992). 1.9-A resolution structure of fasciculin 1, an anti-acetylcholinesterase toxin from green mamba snake venom. J Biol Chem 267 : 22122 22130.
15. Ducancel F (2005). Endothelin-like peptides. Cell Mol Life Sci 62 : 2828 2839.
16. Evers A, Klabunde T (2005). Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. J Med Chem 48 : 1088 1097.
17. Evers A, Hessler G, Matter H, Klabunde T (2005). Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols. J Med Chem 48 : 5448 5465.
18. Favreau P, Gilles N, Lamthanh H, Bournaud R, Shimahara T, Bouet F et al. (2001). A new omega-conotoxin that targets N-type voltage-sensitive calcium channels with unusual specificity. Biochemistry 40 : 14567 14575.
19. Fruchart-Gaillard C, Mourier G, Marquer C, Menez A, Servent D (2006). Identification of various allosteric interaction sites on M1 muscarinic receptor using 125I-Met35-oxidized muscarinic toxin 7. Mol Pharmacol 69 : 1641 1651.
20. Gray K, Short J, Ventura S (2008). The alpha1A-adrenoceptor gene is required for the alpha1L-adrenoceptor-mediated response in isolated preparations of the mouse prostate. Br J Pharmacol 155 : 103 109.
21. Harvey AL (2001). Twenty years of dendrotoxins. Toxicon 39 : 15 26.
22. Harvey AL, Kornisiuk E, Bradley KN, Cervenansky C, Duran R, Adrover M et al. (2002). Effects of muscarinic toxins MT1 and MT2 from green mamba on different muscarinic cholinoceptors. Neurochem Res 27 : 1543 1554.
23. Hiraoka Y, Ohmura T, Sakamoto S, Hayashi H, Muramatsu I (1995). Identification of alpha 1-adrenoceptor subtypes in the rabbit prostate. J Auton Pharmacol 15 : 271 278.
24. Jolkkonen M, Adem A, Hellman U, Wernstedt C, Karlsson E (1995). A snake toxin against muscarinic acetylcholine receptors: amino acid sequence, subtype specificity and effect on guinea-pig ileum. Toxicon 33 : 399 410.
25. Jolkkonen M, Oras A, Toomela T, Karlsson E, Jarv J, Akerman KE (2001). Kinetic evidence for different mechanisms of interaction of black mamba toxins MT alpha and MT beta with muscarinic receptors. Toxicon 39 : 377 382.
26. Joubert FJ (1985). The amino acid sequence of protein CM-3 from Dendroaspis polylepis polylepis (black mamba) venom. Int J Biochem 17 : 695 699.
27. Kenakin T (2009). A Pharmacology Primer: Theory, Application, and Methods, Vol. 3. Elsevier Academic Press : London.
28. Kenakin T (2004). Principles: receptor theory in pharmacology. Trends Pharmacol Sci 25 : 186 192.
29. Kenakin T, Jenkinson S, Watson C (2006). Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 319 : 710 723.
30. King GF, Gentz MC, Escoubas P, Nicholson GM (2008). A rational nomenclature for naming peptide toxins from spiders and other venomous animals. Toxicon 52 : 264 276.
31. Klebe G (2006). Virtual ligand screening: strategies, perspectives and limitations. Drug Discov Today 11 : 580 594.
32. Koshimizu TA, Tanoue A, Hirasawa A, Yamauchi J, Tsujimoto G (2003). Recent advances in alpha1-adrenoceptor pharmacology. Pharmacol Ther 98 : 235 244.
33. Kukkonen A, Perakyla M, Akerman KE, Nasman J (2004). Muscarinic toxin 7 selectivity is dictated by extracellular receptor loops. J Biol Chem 279 : 50923 50929.
34. Kumar TK, Jayaraman G, Lee CS, Arunkumar AI, Sivaraman T, Samuel D et al. (1997). Snake venom cardiotoxins-structure, dynamics, function and folding. J Biomol Struct Dyn 15 : 431 463.
35. Michelotti GA, Price DT, Schwinn DA (2000). Alpha 1-adrenergic receptor regulation: basic science and clinical implications. Pharmacol Ther 88 : 281 309.
36. Morishima S, Tanaka T, Yamamoto H, Suzuki F, Akino H, Yokoyama O et al. (2007). Identification of alpha-1L and alpha-1A adrenoceptors in human prostate by tissue segment binding. J Urol 177 : 377 381.
37. Mourier G, Dutertre S, Fruchart-Gaillard C, Menez A, Servent D (2003). Chemical synthesis of MT1 and MT7 muscarinic toxins: critical role of Arg-34 in their interaction with M1 muscarinic receptor. Mol Pharmacol 63 : 26 35.
38. Muramatsu I, Morishima S, Suzuki F, Yoshiki H, Anisuzzaman AS, Tanaka T et al. (2008). Identification of alpha 1L-adrenoceptor in mice and its abolition by alpha 1A-adrenoceptor gene knockout. Br J Pharmacol 155 : 1224 1234.
39. Nielsen DB, Dykert J, Rivier JE, McIntosh JM (1994). Isolation of Lys-conopressin-G from the venom of the worm-hunting snail, Conus imperialis. Toxicon 32 : 845 848.
40. Oshita M, Kigoshi S, Muramatsu I (1991). Three distinct binding sites for [3H]-prazosin in the rat cerebral cortex. Br J Pharmacol 104 : 961 965.
41. Palea S, Chang DF, Rekik M, Regnier A, Lluel P (2008). Comparative effect of alfuzosin and tamsulosin on the contractile response of isolated rabbit prostatic and iris dilator smooth muscles: possible model for intraoperative floppy-iris syndrome. J Cataract Refract Surg 34 : 489 496.
42. Rajagopalan N, Pung YF, Zhu YZ, Wong PT, Kumar PP, Kini RM (2007). Beta-cardiotoxin: a new three-finger toxin from Ophiophagus hannah (king cobra) venom with beta-blocker activity. Faseb J 21 : 3685 3695.
43. Servent D, Menez A (2001). Snake neurotoxins that interact with nicotinic acetylcholine receptors. In : Massaro EJ (ed.). Handbook of Neurotoxicology. Humana Press, Inc. : Totowa, NJ, pp. 385 425.
44. Servent D, Fruchart-Gaillard C (2009). Muscarinic toxins: tools for the study of the pharmacological and functional properties of muscarinic receptors. J Neurochem 109 : 1193 1202.
45. Sharpe IA, Gehrmann J, Loughnan ML, Thomas L, Adams DA, Atkins A et al. (2001). Two new classes of conopeptides inhibit the alpha1-adrenoceptor and noradrenaline transporter. Nat Neurosci 4 : 902 907.
46. Su TH, Morishima S, Suzuki F, Yoshiki H, Anisuzzaman AS, Tanaka T et al. (2008). Native profiles of alpha(1A)-adrenoceptor phenotypes in rabbit prostate. Br J Pharmacol 155 : 906 912.
47. Tambaro S, Ruiu S, Dessi C, Mongeau R, Marchese G, Pani L (2005). Evaluation of tamsulosin and alfuzosin activity in the rat vas deferens: relevance to ejaculation delays. J Pharmacol Exp Ther 312 : 710 717.
48. Vauquelin G, Van Liefde I, Birzbier BB, Vanderheyden PM (2002a). New insights in insurmountable antagonism. Fundam Clin Pharmacol 16 : 263 272.
49. Vauquelin G, Van Liefde I, Vanderheyden P (2002b). Models and methods for studying insurmountable antagonism. Trends Pharmacol Sci 23 : 514 518.
50. de Weille JR, Schweitz H, Maes P, Tartar A, Lazdunski M (1991). Calciseptine, a peptide isolated from black mamba venom, is a specific blocker of the L-type calcium channel. Proc Natl Acad Sci USA 88 : 2437 2440.
51. Wu PL, Lee SC, Chuang CC, Mori S, Akakura N, Wu WG et al. (2006). Non-cytotoxic cobra cardiotoxin A5 binds to alpha(v)beta3 integrin and inhibits bone resorption. Identification of cardiotoxins as non-RGD integrin-binding proteins of the Ly-6 family. J Biol Chem 281 : 7937 7945.